Literature DB >> 23130457

The impact and disease burden of thalassemia in Thailand: a population-based study in 2010.

Nattiya Teawtrakul1, Kanchana Chansung, Chittima Sirijerachai, Chinadol Wanitpongpun, Kaewjai Thepsuthammarat.   

Abstract

BACKGROUND: Thalassemia is a common genetic disease in Thailand. However, current data on the impact and disease burden of thalassemia in Thailand remains limited.
OBJECTIVE: To determine the admission rate, OPD visit rate, mortality rate, hospital cost, length of hospital stay, blood transfusion rate and major complications rate in patients with thalassemia. MATERIAL AND
METHOD: The present study analyzed the data of inpatients and outpatients with a diagnosis of thalssemia according to ICD10 coded D56, D56.0, D56.1, D56.2, D56.3, D56.4, D56.8 and D56.9 which came from nationwide health financing schemes in the fiscal year 2010.
RESULTS: The overall admission rate and OPD visit rate were 154 and 562 per 100,000 populations and higher in children and adolescents. The overall mortality rate was 1.13 per 100,000 populations. The total healthcare cost was 744,998,997 Baht or US$ 23,486,727 per year. Blood transfusion rate was significantly higher among children and adolescents. The thalassemia-related complications commonly occurred at the second and the third decades of life.
CONCLUSION: The admission rate, OPD visit rate, blood transfusion rate were higher among children and adolescents. The total healthcare cost was high which was nearly 745 million Baht per year. The hospital cost, length of stay and major complications were increased with age.

Entities:  

Mesh:

Year:  2012        PMID: 23130457

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  7 in total

1.  Applying molecular immunohaematology to regularly transfused thalassaemic patients in Thailand.

Authors:  Pairaya Rujirojindakul; Willy A Flegel
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

Review 2.  Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.

Authors:  Annita Kolnagou; Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-12-26

Review 3.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

4.  A comprehensive ethnic-based analysis of alpha thalassaemia allelle frequency in northern Thailand.

Authors:  Mattapong Kulaphisit; Jatupol Kampuansai; Kamonlak Leecharoenkiat; Methi Wathikthinnakon; Daoroong Kangwanpong; Thongperm Munkongdee; Saovaros Svasti; Suthat Fucharoen; Duncan R Smith; Pathrapol Lithanatudom
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

5.  Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study.

Authors:  Shaikha Alshamsi; Samer Hamidi; Hacer Ozgen Narci
Journal:  BMC Health Serv Res       Date:  2022-03-05       Impact factor: 2.655

6.  A review of accessibility of administrative healthcare databases in the Asia-Pacific region.

Authors:  Dominique Milea; Soraya Azmi; Praveen Reginald; Patrice Verpillat; Clement Francois
Journal:  J Mark Access Health Policy       Date:  2015-07-20

Review 7.  Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.

Authors:  George J Kontoghiorghes; Christina N Kontoghiorghe
Journal:  Cells       Date:  2020-06-12       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.